HS 10365
Alternative Names: HS-10365Latest Information Update: 30 Nov 2023
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 25 Sep 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) in China (PO) (NCT06147570)
- 14 Apr 2023 Safety, efficacy and pharmacokinetics data from the phase I/II trial in Solid tumours presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 09 Nov 2021 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (PO) (NCT05207787)